EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Increased expression of the cGMP-inhibited cAMP-specific and cGMP binding cGMP-specific phosphodiesterases in models of pulmonary hypertension



Increased expression of the cGMP-inhibited cAMP-specific and cGMP binding cGMP-specific phosphodiesterases in models of pulmonary hypertension



British Journal of Pharmacology 137(8): 1187-1194, December



1 Chronic hypoxic treatment of rats (to induce pulmonary hypertension, PHT) for 14 days increased cGMP-inhibited cAMP specific phosphodiesterase (PDE3) and cGMP binding cGMP specific phosphodiesterase (PDE5) activities in pulmonary arteries. The objective of this study was to establish the molecular basis for these changes in both animal and cell models of PHT. In this regard, RT-PCR and quantitative Western blotting analysis was applied to rat pulmonary artery homogenates and human pulmonary 'artery' smooth muscle cell (HPASMC) lysates. 2 PDE3A/B gene transcript levels were increased in the main, first, intrapulmonary and resistance pulmonary arteries by chronic hypoxia. mRNA transcript and protein levels of PDE5A2 in the main and first branch pulmonary arteries were also increased by chronic hypoxia, with no effect on PDE5A1/A2 in the intra-pulmonary and resistance vessels. 3 The expression of PDE3A was increased in HPASMCs maintained under chronic hypoxic conditions for 14 days. This may be mediated via a protein kinase A-dependent mechanism, as treatment of cells with Br-cAMP (100 muM) mimicked chronic hypoxia in increasing PDE3A expression, while the PKA inhibitor, H8 peptide (50 muM) abolished the hypoxic-dependent increase in PDE3A transcript. 4 We also found that the treatment of HPASMCs with the inhibitor of kappaB degradation Tosyl-Leucyl-Chloro-Ketone (TLCK, 50 muM) reduced PDE5 transcript levels, suggesting a role for this transcription factor in the regulation of PDE5 gene expression. 5 Our results show that increased expression of PDE3 and PDE5 might explain some changes in vascular reactivity of pulmonary vessels from rats with PHT. We also report that NF-kappaB might regulate basal PDE5 expression.

(PDF emailed within 1 workday: $29.90)

Accession: 035118057

Download citation: RISBibTeXText



Related references

Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. British Journal of Pharmacology 137(8): 1187-1194, 2002

The subunit of the rod photoreceptor cGMP phosphodiesterase can modulate the proteolysis of two cGMP binding cGMP-specific phosphodiesterases (PDE6 and PDE5) by caspase-3. Cellular Signalling 13(10): 735-741, 2001

The gamma subunit of the rod photoreceptor cGMP phosphodiesterase can modulate the proteolysis of two cGMP binding cGMP-specific phosphodiesterases (PDE6 and PDE5) by caspase-3. Cellular Signalling 13(10): 735-741, 2001

Studies of the molecular mechanism of discrimination between cGMP and cAMP in the allosteric sites of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). Journal of Biological Chemistry 274(41): 29038-29041, 1999

Hydropathic analysis and mutagenesis of the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). cGMP versus cAMP substrate selectivity. Biochemistry 37(12): 4200-4205, 1998

Individual cerebellar Purkinje cells express different cGMP phosphodiesterases In vivo phosphorylation of cGMP-specific PDE as an indicator of cGMP-dependent protein kinase activation. Journal of Neuroscience 23(16): 6452-6459, July 23, 2003

Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): in vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation. Journal of Neuroscience 23(16): 6452-6459, 2003

CGMP regulates platelet cAMP levels through effects of both cGMP-inhibitied and cGMP-stimulated phosphodiesterases. FASEB Journal 10(6): A1374, 1996

Genomic origin and transcriptional regulation of two variants of cGMP-binding cGMP-specific phosphodiesterases. European Journal of Biochemistry 262(3): 866-872, June, 1999

Cloning, expression and binding of the high affinity cGMP binding domain from human cGMP-binding, cGMP specific phosphodiesterase. FASEB Journal 12(4): A148, March 17, 1998

Specific high affinity zinc binding to lung cGMP-binding cGMP-specific phosphodiesterase is consistent with the presence of a conserved zinc binding motif in cyclic nucleotide phosphodiesterases. FASEB Journal 7(7): A1151, 1993

The GAF domain of the cGMP-binding, cGMP-specific phosphodiesterase (PDE5) is a sensor and a sink for cGMP. Biochemistry 47(11): 3534-3543, 2008

Identification of key amino acids in a conserved cGMP-binding site of cGMP-binding phosphodiesterases. A putative NKXnD motif for cGMP binding. Journal of Biological Chemistry 271(36): 22240-4, 1996

Allosteric activation of cGMP-specific, cGMP-binding phosphodiesterase (PDE5) by cGMP. Biochemistry (American Chemical Society) 41(30): 72-9, 2002

CGMP-binding cGMP-specific phosphodiesterase exhibits positive cooperativity in binding cGMP at the allosteric sites. FASEB Journal 8(7): A1290, 1994